Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE:IGC) will demonstrate its Agentic Harmonization Assistant (AHA), an AI platform for automating harmonization and analysis of complex biomedical datasets, at ADPD 2026 in collaboration with the Alzheimer's Disease Data Initiative (ADDI).
AHA targets integration of clinical trial data, imaging, and other biomedical sources to reduce manual preparation time and support development of IGC-AD1 in the Phase 2 CALMA trial.
IGC Pharma (NYSE:IGC) announced on February 26, 2026 that it filed utility patent applications covering the architectural framework of its AI-based Agentic Harmonization Assistant (AHA). IGC says AHA standardizes heterogeneous Alzheimer's datasets; the company has harmonized 15 datasets and advanced AHA to a semi-final AI evaluation.
The filings aim to protect AHA's design and methodologies while IGC continues CALMA clinical trial work and plans additional AHA details at the upcoming ADPD conference.
IGC Pharma (NYSE American: IGC) announced that Ascendiant Capital Markets issued updated equity research coverage and raised its price target to $5.00 per share on February 24, 2026.
IGC noted analyst views are those of the analyst firm and provided a link to obtain the full report from Ascendiant Capital Markets.
IGC Pharma (NYSE:IGC) added Visionary Investigators Network (VIN) as a clinical research site for its Phase 2 CALMA trial of IGC-AD1 to treat agitation associated with Alzheimer's disease dementia. The company reported approximately 70% of planned enrollment is completed.
VIN's Coconut Grove site in Miami will support ongoing enrollment using a practice-integrated model and is led by Dr. Andrew Lerman with a dedicated clinical trial coordinator.
IGC Pharma (NYSE American: IGC) announced that the Canadian Intellectual Property Office issued a Notice of Allowance for patent No. 3,095,729, securing composition protection for IGC-AD1 across key North American jurisdictions.
IGC said the allowance covers the low-dose THC combination formulation as the Phase 2 CALMA trial approaches enrollment completion (≈70% enrolled).
IGC Pharma (NYSE American: IGC) will participate in a fireside chat hosted by Ascendiant Capital Markets on February 18, 2026 at 1:00 p.m. ET. CEO Ram Mukunda and CCO Claudia Grimaldi will discuss Phase 2 CALMA trial progress, enrollment momentum, regulatory developments, and the company’s AI-driven precision medicine platform.
The presentation will also cover progress across IGC’s broader pipeline of disease-modifying Alzheimer’s candidates and management’s fiscal 2026 milestones and strategic priorities.
IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners published an updated equity research report on February 10, 2026. The report reiterates a Buy rating and sets a $3.00 price target per share. IGC disclaims endorsement and does not guarantee the report's accuracy.
IGC Pharma (NYSE:IGC) expanded its Phase 2 CALMA trial for IGC-AD1 into Colombia by adding Grupo de Neurociencias de Antioquia (GNA), increasing the clinical network to 23 active sites across 26 locations in the US and Canada plus Colombia. CALMA has reached approximately 70% of planned enrollment with completion expected by mid-2026, the operational gating step before database lock and topline results. GNA brings longitudinal cohorts and biomarker expertise; Dr. Claudia Ramos will serve as Principal Investigator, supported by GNA leadership and multidisciplinary teams.
IGC Pharma (NYSE:IGC) reported reaching approximately 70% enrollment in its Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer’s disease. The company has about 23 active sites across 26 locations and expects to complete enrollment by mid-2026, moving toward database lock and topline results.
IGC said enrollment uses a hybrid decentralized model to expand patient access; efficacy outcomes are not analyzed ongoing to preserve blinding and trial integrity.
IGC Pharma (NYSE American: IGC) announced on January 22, 2026 that Integrative Clinical Trials, LLC in Brooklyn, New York, has joined its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.
The new site, led by Principal Investigator Dr. Inna Yuryev-Golger, MD, expands the trial's clinical footprint in a major metropolitan area and is expected to support patient enrollment and diversity given the site's CNS research experience. IGC-AD1 is being studied in a randomized, double-blind, placebo-controlled Phase 2 trial. The company said the site addition strengthens trial execution and data quality as CALMA advances.